

# Carolina Garcia-Vidal

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6661499/publications.pdf>

Version: 2024-02-01

185  
papers

8,551  
citations

53789

45  
h-index

54911

84  
g-index

200  
all docs

200  
docs citations

200  
times ranked

9269  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA). <i>Haematologica</i> , 2023, 108, 22-33.	3.5	15
2	Personalized Therapy Approach for Hospitalized Patients with Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2022, 74, 127-132.	5.8	36
3	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. <i>Blood Advances</i> , 2022, 6, 2427-2433.	5.2	46
4	Impact of Empirical Antibiotic Regimens on Mortality in Neutropenic Patients with Bloodstream Infection Presenting with Septic Shock. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0174421.	3.2	28
5	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 271-279.	2.9	1
6	Main Acquired Risk Factors of Different Fungal Diseases. , 2022, , .		0
7	Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19. <i>Haematologica</i> , 2022, 107, 1731-1735.	3.5	11
8	Emergence of Progressive Mutations in SARS-CoV-2 From a Hematologic Patient With Prolonged Viral Replication. <i>Frontiers in Microbiology</i> , 2022, 13, 826883.	3.5	7
9	C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. <i>Scientific Reports</i> , 2022, 12, 5250.	3.3	11
10	Practical tips for managing FLT3 mutated acute myeloid leukemia with midostaurin. <i>Expert Review of Hematology</i> , 2022, 15, 203-214.	2.2	3
11	Efficacy of early transfusion of convalescent plasma with high titer SARS-CoV-2 neutralizing antibodies in hospitalized patients with COVID-19. <i>Transfusion</i> , 2022, 62, 974-981.	1.6	9
12	Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). <i>Leukemia</i> , 2022, 36, 1215-1226.	7.2	19
13	Bacterial co-infection at hospital admission in patients with COVID-19. <i>International Journal of Infectious Diseases</i> , 2022, 118, 197-202.	3.3	41
14	Resistance to empirical $\beta$ -lactams recommended in febrile neutropenia guidelines in Gram-negative bacilli bloodstream infections in Spain: a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2017-2023.	3.0	5
15	Real-Life Use of Ceftolozane/Tazobactam for the Treatment of Bloodstream Infection Due to <i>Pseudomonas aeruginosa</i> in Neutropenic Hematologic Patients: a Matched Control Study (ZENITH). <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0174421.	2.2	3
16	Clinical Presentation and Outcome of COVID-19 in a Latin American Versus Spanish Population: Matched Case-Control Study. <i>Infectious Diseases and Therapy</i> , 2022, 11, 1243-1251.	4.0	2
17	Impact of SARS-CoV-2 viral load and duration of symptoms before hospital admission on the mortality of hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 1321-1328.	4.7	15
18	When and which patients should receive remdesivir?. <i>Lancet</i> , The, 2022, 399, 1918-1920.	13.7	2

#	ARTICLE	IF	CITATIONS
19	Correction to: Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. Open Forum Infectious Diseases, 2022, 9, .	0.9	0
20	Cytokine response as a biomarker for early diagnosis and outcome prediction of stem cell transplant recipients and acute leukemia patients with invasive aspergillosis. Medical Mycology, 2022, 60, .	0.7	1
21	Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español. Neurología, 2021, 36, 50-60.	0.7	15
22	Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clinical Microbiology and Infection, 2021, 27, 83-88.	6.0	636
23	Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection, 2021, 49, 215-231.	4.7	63
24	Do high MICs predict the outcome in invasive fusariosis?. Journal of Antimicrobial Chemotherapy, 2021, 76, 1063-1069.	3.0	28
25	Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. Journal of Infection, 2021, 82, 76-83.	3.3	9
26	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. Archivos De Bronconeumología, 2021, 57, 79-82.	0.8	13
27	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. ERJ Open Research, 2021, 7, 00888-2020.	2.6	13
28	Factors Associated With Short-Term Eradication of Rectal Colonization by KPC-2 Producing Klebsiella pneumoniae in an Outbreak Setting. Frontiers in Microbiology, 2021, 12, 630826.	3.5	2
29	Real-life use of remdesivir in hospitalized patients with COVID-19. Revista Espanola De Quimioterapia, 2021, 34, 136-140.	1.3	20
30	Antibiotic-resistant microorganisms in patients with bloodstream infection of intraabdominal origin: risk factors and impact on mortality. Infection, 2021, 49, 693-702.	4.7	7
31	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. PLoS ONE, 2021, 16, e0247251.	2.5	38
32	Risk Factors for Mortality in Hematopoietic Stem Cell Transplantation Recipients with Bloodstream Infection: Points To Be Addressed by Future Guidelines. Transplantation and Cellular Therapy, 2021, 27, 501.e1-501.e6.	1.2	9
33	Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response. BMC Infectious Diseases, 2021, 21, 296.	2.9	24
34	Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Case-Control Study. Infectious Diseases and Therapy, 2021, 10, 955-970.	4.0	2
35	Machine Learning to Assess the Risk of Multidrug-Resistant Gram-Negative Bacilli Infections in Febrile Neutropenic Hematological Patients. Infectious Diseases and Therapy, 2021, 10, 971-983.	4.0	14
36	Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients. PLoS ONE, 2021, 16, e0240200.	2.5	36

#	ARTICLE	IF	CITATIONS
37	Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. Open Forum Infectious Diseases, 2021, 8, ofab169.	0.9	20
38	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. Lancet Regional Health - Europe, The, 2021, 3, 100041.	5.6	35
39	Changing epidemiology of catheter-related bloodstream infections in neutropenic oncohematological patients. PLoS ONE, 2021, 16, e0251010.	2.5	16
40	Early Stepdown From Echinocandin to Fluconazole Treatment in Candidemia: A Post Hoc Analysis of Three Cohort Studies. Open Forum Infectious Diseases, 2021, 8, ofab250.	0.9	11
41	8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncology, The, 2021, 22, e254-e269.	10.7	89
42	Multidrug-resistant, gram-negative infections in high-risk hematologic patients: an update on epidemiology, diagnosis and treatment. Current Opinion in Infectious Diseases, 2021, 34, 314-322.	3.1	7
43	Pulse oximetry is an essential tool that saves lives: a call for standardisation. European Respiratory Journal, 2021, 57, 2100815.	6.7	0
44	Impact of Inflammatory Response Modifiers on the Incidence of Hospital-Acquired Infections in Patients with COVID-19. Infectious Diseases and Therapy, 2021, 10, 1407-1418.	4.0	5
45	8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncology, The, 2021, 22, e270-e280.	10.7	65
46	Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study). Antimicrobial Agents and Chemotherapy, 2021, 65, e0004521.	3.2	18
47	Gustatory and olfactory dysfunctions in hospitalised patients with COVID-19 pneumonia: a prospective study. BMJ Open, 2021, 11, e040775.	1.9	3
48	Impact of remdesivir according to the pre-admission symptom duration in patients with COVID-19. Journal of Antimicrobial Chemotherapy, 2021, 76, 3296-3302.	3.0	30
49	Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 3020-3028.	3.0	5
50	Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.. Allergologia Et Immunopathologia, 2021, 49, 118-127.	1.7	8
51	COVID-19 and fungal infections: Etiopathogenesis and therapeutic implications. Revista Espanola De Quimioterapia, 2021, 34, 72-75.	1.3	2
52	Changing Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Fungi (Basel, Switzerland), 2021, 7, 848.	3.5	23
53	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
54	Inappropriate Empirical Antibiotic Treatment in High-risk Neutropenic Patients With Bacteremia in the Era of Multidrug Resistance. Clinical Infectious Diseases, 2020, 70, 1068-1074.	5.8	66

#	ARTICLE	IF	CITATIONS
55	Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. Bone Marrow Transplantation, 2020, 55, 603-612.	2.4	33
56	Performance of differential time to positivity as a routine diagnostic test for catheter-related bloodstream infections: a single-centre experience. Clinical Microbiology and Infection, 2020, 26, 383.e1-383.e7.	6.0	14
57	Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection. Clinical Microbiology and Infection, 2020, 26, 345-350.	6.0	27
58	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. Autoimmunity Reviews, 2020, 19, 102429.	5.8	197
59	An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia. Journal of Antimicrobial Chemotherapy, 2020, 75, 730-737.	3.0	17
60	Fungal co-infection in COVID-19 patients: Should we be concerned?. Revista Iberoamericana De Micologia, 2020, 37, 41-46.	0.9	113
61	Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: when management reasoning eclipses evidence-based medicine. Journal of Antimicrobial Chemotherapy, 2020, 75, 3096-3098.	3.0	1
62	Efficacy of extended infusion of Î²-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE). Trials, 2020, 21, 412.	1.6	6
63	Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. European Respiratory Journal, 2020, 56, 2000773.	6.7	5
64	Promoting the use of social networks in pneumonia. Pneumonia (Nathan Qld ), 2020, 12, 3.	6.1	12
65	Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients. Leukemia and Lymphoma, 2020, 61, 1565-1574.	1.3	8
66	Fungal infections following treatment with monoclonal antibodies and other immunomodulatory therapies. Revista Iberoamericana De Micologia, 2020, 37, 5-16.	0.9	14
67	Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies. Enfermedades Infecciosas Y Microbiología Clínica, 2020, 38, 174-181.	0.5	22
68	Up-to-Date Infection Control Practices for Febrile Neutropenic Patients. Current Treatment Options in Infectious Diseases, 2020, 12, 77-86.	1.9	2
69	Can Artificial Intelligence Improve the Management of Pneumonia. Journal of Clinical Medicine, 2020, 9, 248.	2.4	30
70	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. Critical Care, 2020, 24, 117.	5.8	19
71	Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	33
72	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. Medical Sciences (Basel, Switzerland), 2020, 8, 6.	2.9	6

#	ARTICLE	IF	CITATIONS
73	1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study. Open Forum Infectious Diseases, 2020, 7, S795-S796.	0.9	0
74	Profile of patients with COVID-19 treated in Spanish emergency departments during the 2020 pandemic. Emergencias, 2020, 32, 225-226.	0.6	2
75	Executive summary of clinical practice guideline for the management of invasive diseases caused by Aspergillus: 2018 Update by the GEMICOMED-SEIMC/REIPI. Enfermedades Infecciosas Y Microbiología Clínica, 2019, 37, 535-541.	0.5	46
76	Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia. Journal of Clinical Medicine, 2019, 8, 1150.	2.4	0
77	Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). Journal of Antimicrobial Chemotherapy, 2019, 74, 3315-3327.	3.0	30
78	Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia. Journal of Clinical Medicine, 2019, 8, 961.	2.4	22
79	Artificial intelligence to support clinical decision-making processes. EBioMedicine, 2019, 46, 27-29.	6.1	76
80	Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome. Transplant Infectious Disease, 2019, 21, e13195.	1.7	14
81	Acute liver failure due to visceral leishmaniasis in Barcelona: a case report. BMC Infectious Diseases, 2019, 19, 874.	2.9	9
82	Defining standards of CARE for invasive fungal diseases in solid organ transplant patients. Journal of Antimicrobial Chemotherapy, 2019, 74, ii16-ii20.	3.0	4
83	Posaconazole salvage therapy: The Posifi study. Mycoses, 2019, 62, 526-533.	4.0	9
84	THU0683 – COVERAGE, PREDICTORS OF VACCINATION AND FREQUENCY OF SEVERE INFECTIONS DUE TO STREPTOCOCCUS PNEUMONIAE IN A COHORT OF PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS WITHIN AN EIGHTEEN-YEAR PERIOD. , 2019, , .		1
85	Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies. Clinical Microbiology and Infection, 2019, 25, 447-453.	6.0	40
86	Effect of Combined $\beta$ -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Chest, 2019, 155, 795-804.	0.8	34
87	Usefulness of guideline recommendations for prognosis in patients with candidemia. Medical Mycology, 2019, 57, 659-667.	0.7	24
88	Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. International Journal of Antimicrobial Agents, 2019, 53, 520-524.	2.5	59
89	Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning. European Respiratory Journal, 2019, 54, 1902111.	6.7	0
90	Ceftobiprole for the treatment of pneumonia. Revista Espanola De Quimioterapia, 2019, 32 Suppl 3, 17-23.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Prophylaxis of mould infections. Revista Espanola De Quimioterapia, 2019, 32 Suppl 2, 59-62.	1.3	1
92	Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. Clinical Infectious Diseases, 2018, 67, 958-961.	5.8	9
93	Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis. Journal of Infection, 2018, 76, 342-347.	3.3	15
94	Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients. European Respiratory Journal, 2018, 51, 1701332.	6.7	11
95	Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. European Respiratory Journal, 2018, 51, 1702215.	6.7	45
96	Antimicrobial Resistance Among Streptococcus pneumoniae. , 2018, , 13-38.		20
97	Community-acquired pneumonia as an emergency condition. Current Opinion in Critical Care, 2018, 24, 531-539.	3.2	41
98	Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Journal of Global Antimicrobial Resistance, 2018, 15, 136-139.	2.2	43
99	Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients. Biology of Blood and Marrow Transplantation, 2018, 24, 2088-2093.	2.0	11
100	Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis- authors' response. Journal of Antimicrobial Chemotherapy, 2018, 73, 1732-1733.	3.0	6
101	Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS ONE, 2018, 13, e0199531.	2.5	60
102	Community-acquired bacterial pneumonia in adult HIV-infected patients. Expert Review of Anti-Infective Therapy, 2018, 16, 579-588.	4.4	15
103	Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. PLoS ONE, 2018, 13, e0200504.	2.5	27
104	Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	23
105	Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy. Revista Espanola De Quimioterapia, 2018, 31, 78-100.	1.3	48
106	Top-ten papers in fungal infection (2015-2017). Revista Espanola De Quimioterapia, 2018, 31 Suppl 1, 32-34.	1.3	0
107	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. Chest, 2017, 151, 1311-1319.	0.8	13
108	Levofloxacin versus azithromycin for treating legionella pneumonia: a propensity score analysis. Clinical Microbiology and Infection, 2017, 23, 653-658.	6.0	38



#	ARTICLE	IF	CITATIONS
109	Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1374-1379.	5.8	19
110	PET/CT added to Duke criteria facilitates diagnosis and monitoring of long-term suppressive therapy of prosthetic endocarditis. <i>Infectious Diseases</i> , 2017, 49, 698-701.	2.8	5
111	Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 3443-3452.	3.0	20
112	Has Mortality of Community-Acquired Pneumonia Really Reduced?. <i>Clinical Pulmonary Medicine</i> , 2017, 24, 258-262.	0.3	1
113	Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 547-5553.	3.0	44
114	Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. <i>Mycoses</i> , 2017, 60, 79-88.	4.0	7
115	Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. <i>PLoS ONE</i> , 2017, 12, e0182436.	2.5	28
116	Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2120.	4.1	168
117	Mortality of CAP reduced in the UK: is this enough?. <i>Thorax</i> , 2016, 71, 979-980.	5.6	1
118	Declining mortality among hospitalized patients with community-acquired pneumonia. <i>Clinical Microbiology and Infection</i> , 2016, 22, 567.e1-567.e7.	6.0	40
119	Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. <i>Respirology</i> , 2016, 21, 1411-1418.	2.3	30
120	Biomarkers for predicting short-term mortality in community-acquired pneumonia: A systematic review and meta-analysis. <i>Journal of Infection</i> , 2016, 72, 273-282.	3.3	84
121	Breakthrough candidaemia in the era of broad-spectrum antifungal therapies. <i>Clinical Microbiology and Infection</i> , 2016, 22, 181-188.	6.0	44
122	Causes of Death in a Contemporary Cohort of Patients with Invasive Aspergillosis. <i>PLoS ONE</i> , 2015, 10, e0120370.	2.5	45
123	Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 583-590.	6.0	51
124	A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains. <i>Clinical Microbiology and Infection</i> , 2015, 21, 684.e1-684.e9.	6.0	19
125	The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. <i>BMJ Open</i> , 2015, 5, e006251-e006251.	1.9	42
126	Impact of an Educational Program to Reduce Healthcare Resources in Community-Acquired Pneumonia: The EDUCAP Randomized Controlled Trial. <i>PLoS ONE</i> , 2015, 10, e0140202.	2.5	10



#	ARTICLE	IF	CITATIONS
127	Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacology & Toxicology, 2014, 15, 52.	2.4	16
128	Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplantation, 2014, 49, 824-830.	2.4	87
129	Environmental variables associated with an increased risk of invasive aspergillosis. Clinical Microbiology and Infection, 2014, 20, O939-O945.	6.0	37
130	Management of community-acquired pneumonia in older adults. Therapeutic Advances in Infectious Disease, 2014, 2, 3-16.	1.8	68
131	Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors. Journal of Infection, 2014, 69, 387-395.	3.3	16
132	Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. Supportive Care in Cancer, 2014, 22, 603-610.	2.2	67
133	Impact of pre-hospital antibiotic use on community-acquired pneumonia. Clinical Microbiology and Infection, 2014, 20, O531-O537.	6.0	9
134	Incidence, timing and risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. Journal of Infection, 2014, 68, 534-541.	3.3	34
135	Clinical Features, Etiology and Outcomes of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2014, 9, e105854.	2.5	45
136	Prognostic value of serum albumin levels in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 415-423.	3.3	97
137	Prediction of prognosis by markers in community-acquired pneumonia. Expert Review of Anti-Infective Therapy, 2013, 11, 917-929.	4.4	20
138	Exaggerated Insect Bite Reaction Related to Chronic Leukemia. Mayo Clinic Proceedings, 2013, 88, e37.	3.0	1
139	Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. Journal of Infection, 2013, 66, 27-33.	3.3	76
140	Clinical Features, Etiology, and Outcomes of Community-Acquired Pneumonia in Patients With Diabetes Mellitus. Medicine (United States), 2013, 92, 42-50.	1.0	35
141	Pathogenesis of invasive fungal infections. Current Opinion in Infectious Diseases, 2013, 26, 270-276.	3.1	85
142	Advances in antibiotic therapy for community-acquired pneumonia. Current Opinion in Pulmonary Medicine, 2013, 19, 209-215.	2.6	15
143	Community-Acquired Legionella pneumophila Pneumonia. Medicine (United States), 2013, 92, 51-60.	1.0	102
144	Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques. PLoS ONE, 2013, 8, e60273.	2.5	329

#	ARTICLE	IF	CITATIONS
145	Rainfall Is a Risk Factor for Sporadic Cases of Legionella pneumophila Pneumonia. PLoS ONE, 2013, 8, e61036.	2.5	47
146	Molecular Epidemiology of Nontypeable Haemophilus influenzae Causing Community-Acquired Pneumonia in Adults. PLoS ONE, 2013, 8, e82515.	2.5	35
147	Increase in Bloodstream Infection Due to Vancomycin-Susceptible Enterococcus faecium in Cancer Patients: Risk Factors, Molecular Epidemiology and Outcomes. PLoS ONE, 2013, 8, e74734.	2.5	55
148	Effect of Statin Use on Outcomes of Adults with Candidemia. PLoS ONE, 2013, 8, e77317.	2.5	15
149	Should Health Care Systems and Health Care Providers Implement a New Pathway for Hospitalized Patients With Community-Acquired Pneumonia?â€”Reply. Archives of Internal Medicine, 2012, 172, 1771.	3.8	3
150	Effect of a 3-Step Critical Pathway to Reduce Duration of Intravenous Antibiotic Therapy and Length of Stay in Community-Acquired Pneumonia. Archives of Internal Medicine, 2012, 172, 922-8.	3.8	108
151	Timing of antibiotic administration and outcomes of hospitalized patients with community-acquired and healthcare-associated pneumonia. Clinical Microbiology and Infection, 2012, 18, 1149-1155.	6.0	30
152	Clinical and microbiological epidemiology of Streptococcus pneumoniae bacteremia in cancer patients. Journal of Infection, 2012, 65, 521-527.	3.3	26
153	<b><i>Pseudomonas aeruginosa</i></b> and Mortality after Hospital Admission for Chronic Obstructive Pulmonary Disease. Respiration, 2012, 84, 36-43.	2.6	89
154	Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. Journal of Antimicrobial Chemotherapy, 2011, 66, 657-663.	3.0	208
155	Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Critical Care, 2011, 15, R96.	5.8	121
156	Community-Acquired Pneumonia in Patients With Liver Cirrhosis. Medicine (United States), 2011, 90, 110-118.	1.0	78
157	A prospective cohort study of healthcare visits and rehospitalizations after discharge of patients with community-acquired pneumonia. Respiriology, 2011, 16, 1119-1126.	2.3	32
158	Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. Clinical Microbiology and Infection, 2011, 17, 1659-1665.	6.0	81
159	Effect of statins on outcomes in immunosuppressed patients with bloodstream infection. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 77-82.	2.9	9
160	Predictive factors, microbiology and outcome of patients with parapneumonic effusion. European Respiratory Journal, 2011, 38, 1173-1179.	6.7	100
161	Invasive Aspergillosis Complicating Pandemic Influenza A (H1N1) Infection in Severely Immunocompromised Patients. Clinical Infectious Diseases, 2011, 53, e16-e19.	5.8	91
162	Epidemiology, clinical features and outcomes of pneumonia in patients with chronic kidney disease. Nephrology Dialysis Transplantation, 2011, 26, 2899-2906.	0.7	88

#	ARTICLE	IF	CITATIONS
163	An update on Legionella. Current Opinion in Infectious Diseases, 2010, 23, 152-157.	3.1	115
164	Statins for community-acquired pneumonia: current state of the science. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 143-152.	2.9	42
165	Impact of antibiotic therapy on systemic cytokine expression in pneumococcal pneumonia. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 1243-1251.	2.9	14
166	Mortality of Tuberculosis in Very Old People. Journal of the American Geriatrics Society, 2010, 58, 18-22.	2.6	23
167	Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax, 2010, 65, 77-81.	5.6	97
168	Recent improvement in long-term survival after a COPD hospitalisation. Thorax, 2010, 65, 298-302.	5.6	69
169	Bacteraemia due to extended-spectrum $\beta$ -lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. Journal of Antimicrobial Chemotherapy, 2010, 65, 333-341.	3.0	158
170	Peripheral facial palsy after varicella. Report of two cases and review of the literature. Enfermedades Infecciosas Y Microbiología Clínica, 2010, 28, 504-508.	0.5	15
171	Early and Late Treatment Failure in Community-Acquired Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2009, 30, 154-160.	2.1	32
172	Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. European Respiratory Journal, 2009, 34, 1072-1078.	6.7	141
173	Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. European Journal of Clinical Microbiology and Infectious Diseases, 2009, 28, 331-337.	2.9	90
174	Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respiriology, 2009, 14, 105-111.	2.3	62
175	Clinical features and outcomes of Legionnaires' disease in solid organ transplant recipients. Transplant Infectious Disease, 2009, 11, 78-82.	1.7	38
176	Aetiology of, and risk factors for, recurrent community-acquired pneumonia. Clinical Microbiology and Infection, 2009, 15, 1033-1038.	6.0	58
177	Fungal postoperative spondylodiscitis due to Scedosporium prolificans. Spine Journal, 2009, 9, e1-e7.	1.3	23
178	Paradoxical Reaction of Multiple Cerebral Tuberculomas. Mayo Clinic Proceedings, 2008, 83, 264.	3.0	4
179	Early mortality in patients with community-acquired pneumonia: causes and risk factors. European Respiratory Journal, 2008, 32, 733-739.	6.7	105
180	What is healthcare-associated pneumonia and how is it managed?. Current Opinion in Infectious Diseases, 2008, 21, 168-173.	3.1	30

#	ARTICLE	IF	CITATIONS
181	Effects of systemic steroids in patients with severe community-acquired pneumonia. European Respiratory Journal, 2007, 30, 951-956.	6.7	1,178
182	Artritis reumatoide y tropismo infeccioso. Seminarios De La Fundaci3n Espaola De Reumatologaa, 2007, 8, 68-87.	0.1	1
183	Current clinical management of Legionnairesâ€™ disease. Expert Review of Anti-Infective Therapy, 2006, 4, 995-1004.	4.4	23
184	Echinocandins for Candidemia. New England Journal of Medicine, 2006, 355, 2791-2792.	27.0	3
185	Early, short and long-term mortality in community-acquired pneumonia. Annals of Research Hospitals, 0, 2, 5-5.	0.0	9